Capricor Therapeutics had its Relative Strength (RS) Rating upgraded from 90 to 96 Monday.
Here Are 3 Keys For Successful Stock Investing
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains often have an RS Rating of at least 80 as they launch their biggest climbs.
Capricor Therapeutics has risen more than 5% past a 5.48 entry in a first-stage cup without handle, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% earnings growth last quarter. Sales gains came in at -8%. Look for the next report on or around May 8.
Capricor Therapeutics holds the No. 178 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
